Management of DAA Failures - Gregory T. Everson, MD

Optimize Workshop: Using DAAs in Patients with Cirrhosis and Liver Recipients 2016

Who Should We Treat? What is the “Point-of-No-Return”? - Norah Terrault, MD, MPH, FAASLD

Optimize Workshop: Using DAAs in Patients with Cirrhosis and Liver Recipients 2016

Treatment Experienced GT3 patient with Cirrhosis - Geoffrey McCaughan, MD, PhD

Optimize Workshop: Using DAAs in Patients with Cirrhosis and Liver Recipients 2016

Is Treatment Cost-effective? - Kosh Agarwal, MD

Optimize Workshop: Using DAAs in Patients with Cirrhosis and Liver Recipients 2016

What Are the Treatment Options? - Xavier Forns, MD

Optimize Workshop: Using DAAs in Patients with Cirrhosis and Liver Recipients 2016

When to Treat HCV in a Waiting List Patient? - Stefano Fagiuoli, MD

Optimize Workshop: Using DAAs in Patients with Cirrhosis and Liver Recipients 2016

Achieving SVR in CTP C – MELD Purgatory - Christophe Duvoux, MD

Optimize Workshop: Using DAAs in Patients with Cirrhosis and Liver Recipients 2016

What Are the Treatment Options? - Maria Londoño, MD

Optimize Workshop: Using DAAs in Patients with Cirrhosis and Liver Recipients 2016

Use of HCV+ Donor Grafts - Didier Samuel, MD, PhD

Optimize Workshop: Using DAAs in Patients with Cirrhosis and Liver Recipients 2016

Post-LT Renal Failure and HCV Rx - Peter Ferenci, MD

Optimize Workshop: Using DAAs in Patients with Cirrhosis and Liver Recipients 2016

Obstacles to Treatment: Renal Disease, Ribavirin, DDIs - Michael Charlton, MD

Optimize Workshop: Using DAAs in Patients with Cirrhosis and Liver Recipients 2016

Population attributable fraction of genital inflammation and ulceration in HIV transmission in discordant couples, Lusaka, Zambia, 1994-2012 - K. Wall

International Workshop on HIV Transmission 2015

Heterosexual Transmission of Subtype C HIV-1 Does Not Require Increase Replicative Capacity or Interferon-alpha Resistance - Z. Ende

International Workshop on HIV Transmission 2015

Conserved molecular signatures in gp120 are associated with the genetic bottleneck in SIV, SHIV, and HIV-1 transmission - M. Gonzalez

International Workshop on HIV Transmission 2015

HIV Transmission in the US and fitness effects of drug-resistant viruses - Joel Wertheim, PhD

International Workshop on HIV Transmission 2015

Multiplexed sequencing of HIV-1 env as a measure of viral diversity in HIV-1 infected transmission pairs - E. El-Badry

International Workshop on HIV Transmission 2015

Applications of Next-Generation Sequencing for Identification of Transmitted HIV-1 - K. Brooks

International Workshop on HIV Transmission 2015

New generation of nucleic acid testing assays for acute infections - Michele Owen, PhD

International Workshop on HIV Transmission 2015

Mechanisms by which anti-α4β7 integrin reduces mucosal transmission in SIV macaque model - S. Byrareddy

International Workshop on HIV Transmission 2015

Co-infection of HTLV-1 permits HIV-1 direct infection of female genital epithelium in vitro despite antiretroviral therapy: Implications for HIV-1 vaginal transmission - Y. Tang

International Workshop on HIV Transmission 2015

Early transmission steps - Thomas Hope, PhD

International Workshop on HIV Transmission 2015

Safety and pharmacokinetics of quick dissolving polymeric vaginal films delivering antiretroviral combinations for pre-exposure - P. Srinivasan

International Workshop on HIV Transmission 2015

Pre-Exposure Prophylaxis Modality Preferences among Men who Have Sex with Men - E. Hall

International Workshop on HIV Transmission 2015

Approved Regimens for Non ‐Cirrhotic Patients - Graham Foster, FRCP, PhD

Workshop on HCV Therapy Advances – New Antivirals in Clinical Practice 2015